Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 1
1(50.0%)
2Total
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03833193Not ApplicableUnknown

Moderate Hypofractionated Radiotherapy for Lung Cancer

Role: lead

NCT04787003Phase 1Unknown

Oncolytic Virus (OVV-01) Injection in the Treatment of Patients With Advanced Solid Tumors

Role: lead

NCT03487952Unknown

Evaluation of Lung Nodule Detection With Artificial Intelligence Assisted Computed Tomography in North China

Role: collaborator

All 3 trials loaded